Navigation Links
Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes
Date:5/31/2012

RARITAN, N.J., May 31, 2012 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen), announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the use of canagliflozin, an investigational, oral, once-daily, selective sodium glucose co-transporter 2 (SGLT2) inhibitor, for the treatment of adult patients with type 2 diabetes.

The kidneys of people with type 2 diabetes reabsorb greater amounts of glucose back into the body compared to non-diabetic people, which may contribute to elevated glucose levels. Canagliflozin blocks the reabsorption of glucose by the kidney, increasing glucose excretion and lowering blood glucose levels.

The filing is supported by a comprehensive global Phase 3 clinical development program, which included nine multicenter, randomized clinical studies that enrolled approximately 10,300 patients, representing the largest late-stage development program for an investigational pharmacologic product for the treatment of patients with type 2 diabetes submitted to health authorities to date. The Phase 3 program evaluated the safety and efficacy of canagliflozin across the spectrum of type 2 diabetes and included placebo- and active comparator-controlled studies. The program also included a dedicated cardiovascular study conducted in patients who have or are at high risk for developing cardiovascular disease. Janssen will present data from the Phase 3 studies at future scientific venues, beginning with the Scientific Sessions of the American Diabetes Association in Philadelphia, in June.

Janssen and its affiliates have rights to canagliflozin through a license agreement with Mitsubishi Tanabe Pharma Corporation. Janssen Pharmaceuticals, Inc. has marketing rights in North America, South America, Europe, Middle East, Africa, Australia, New Zealand and parts of Asia.

About Type 2 Diabetes

Type 2 diabetes is a chronic co
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis
2. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
3. AUDIO from Medialink and Ortho-McNeil-Janssen Pharmaceuticals Inc.: Getting Ready for Cold and Flu Season
4. Nominations Open for the 2010 Dr. Paul Janssen Award for Biomedical Research
5. WuXi PharmaTech Enters into Collaboration with J&JPRD, a division of Janssen Pharmaceutica for Preclinical Services and Training
6. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Agrees to $75 Million Settlement for Topamax(R) False Claims Lawsuit
7. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Resolves Investigation of Past TOPAMAX(R) Marketing and Promotional Activities
8. The Pittsburgh Life Sciences Greenhouse Congratulates Diamyd Medical on Its Agreement with Ortho-McNeil-Janssen Pharmaceuticals to Develop Diabetes Therapy
9. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Announces Oncology Research Collaboration Agreement with the Koch Institute for Integrative Cancer Research at MIT
10. Dr. Paul Janssen Award for Biomedical Research Issues Call for Nominations
11. Lilly Makes an Irrevocable Offer to Acquire Janssen Animal Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... July 31, 2015 According to ... by Product (Bioimpedance Analyzers (BIA), Dual-Energy X-ray Absorptiometry (DEXA), ... - Global Analysis & Forecast to 2019", published by ... at $911.1 Million 2014 and is estimated to grow ... of 9.4% from 2014 to 2019. ...
(Date:7/30/2015)... DIEGO , July 30, 2015 /PRNewswire/ ... it has signed a definitive agreement to ... of non-invasive ventilation and sleep-disordered breathing medical ... clinical, innovation and market reputation in China, combined with ResMed,s global leadership in ... people in China ...
(Date:7/30/2015)... , July 30, 2015  EP Global Communications, ... have recently contacted the Company about discussing EPGL,s ... early as Monday, August 3, 2015.  Novartis CEO ... saying that the coming electronic contact lens market ... over the next several years.  Novartis partnered with ...
Breaking Medicine Technology:Body Composition Analyzers Market Worth $1,425.7 Million by 2019 2Body Composition Analyzers Market Worth $1,425.7 Million by 2019 3Body Composition Analyzers Market Worth $1,425.7 Million by 2019 4ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3
... Novel Biomarkers Displaying 90% Sensitivity in Breast ... ... announced today the,discovery and validation of the most frequent DNA alterations detected ... appeared in PLoS ONE. The study entitled, "Identification of,Novel High-Frequency DNA Methylation ...
... GeoVax Labs, Inc. (OTC,Bulletin Board: GOVX), an Atlanta-based ... has retained Financial,Relations Board (FRB), as its Investor ... HIV-1/AIDS vaccine human trial results need to be,conveyed ... AIDS,pandemic," stated Kathy Waller, co-president of FRB., ...
Cached Medicine Technology:Orion Genomics Announces the Discovery of Novel Breast Cancer Biomarkers 2GeoVax Labs, Inc. Selects Financial Relations Board as Investor Relations Counsel 2GeoVax Labs, Inc. Selects Financial Relations Board as Investor Relations Counsel 3GeoVax Labs, Inc. Selects Financial Relations Board as Investor Relations Counsel 4
(Date:7/31/2015)... ... July 31, 2015 , ... Recently, ZKB filed ... Ohio, Western Division (Case No. 3:15-cv-00397) involving the Implanon® contraceptive implant . ... migration of their Implanon® implants, inability to locate the implants, unsuccessful and invasive ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... The alarm was ringing. Hugh Chatfield, survivor ... out of the window, he recalled that his equipment was set up to depict the ... he jumped out of bed. , The photo speaks for itself. Chatfield is also a ...
(Date:7/31/2015)... ... July 31, 2015 , ... Patients with higher levels of ... study published today in Nature Communications and led by researchers from the Icahn School ... variations in the gene RTN1 led to greater production of the related RNT1 protein, ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... proud to announce that their latest designer handbag line will be named for ... an Internet sensation as the first globally recognized model with Down syndrome, gracing ...
(Date:7/31/2015)... ... July 31, 2015 , ... Healthpointe ... a newly redesigned website at Healthpointe.net. The new website will feature a sleek ... The redesign serves to provide smoother interactions between patients and the Healthpointe clinics ...
Breaking Medicine News(10 mins):Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 2Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 3Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 2Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 3Health News:everMaya to Launch Madeline Stuart Handbag Line 2Health News:everMaya to Launch Madeline Stuart Handbag Line 3Health News:Healthpointe Announces Newly Redesigned Website 2
... to reduce levels of bad cholesterol in the blood. Scientists ... the genes that bring about this beneficial effect. ... in the open-access journal PLoS Genetics, the research group has ... infarction and stroke can be prevented if levels of the ...
... writing, helps to ease patients, burden , , FRIDAY, March 14 ... University,s Lombardi Comprehensive Cancer Center for treatment of lymphoma, he ... how his cancer had changed him and how he felt ... IV in his left arm and a pen in his ...
... D.C., and Meet with Elected,Officials, WASHINGTON, March 14 ... Washington, D.C., this April 1 to meet with,congressional leaders ... Disabilities Act, support for epilepsy public health,programs and more ... is one of 50 young people with epilepsy participating ...
... Washington, D.C., and,Meet with Elected Officials, WASHINGTON, ... Schliesmann of Holmen will travel to Washington,D.C., this ... gain their,support for restoration of the Americans with ... more research toward a cure for,epilepsy., Benishek ...
... to Visit Washington, D.C., and Meet With Elected,Officials, ... travel to Washington, D.C., this April 1 to meet ... the,Americans with Disabilities Act, support for epilepsy public health,programs ... Zachery, 15, is one of 50 young people with ...
... NHS Choices ( http://www.nhs.uk ), the,digital ,front ... Live Well package on,pregnancy, aimed at helping ... during,pregnancy., Based on NHS accredited information, ... information about staying healthy and fit during ...
Cached Medicine News:Health News:Fighting Cancer With a Pen 2Health News:Fighting Cancer With a Pen 3Health News:Colorado Youth Named National Epilepsy Spokesperson 2Health News:Wisconsin Youths Named National Epilepsy Spokespersons 2Health News:Tennessee Youth Named National Epilepsy Spokesperson 2
... A necessary addition to ... the Reichert Trial Frame ... and smooth controls for ... robust design, high-quality materials, ...
... The Ultramatic Rx Master is ... years of reliable service and ... that measurably improve procedures. It ... need and want most, including ...
The Maverick Over-The-Wire balloon catheter delivers a new level of performance to meet the changing demands of interventional cardiology....
... Illumination is provided by a cool-running, ... light only what you need to see ... best of all they are maintenance free ... light bulb. Every Phoroptor comes with a ...
Medicine Products: